UA96279C2 - Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogo - Google Patents

Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogo

Info

Publication number
UA96279C2
UA96279C2 UAA200807663A UAA200807663A UA96279C2 UA 96279 C2 UA96279 C2 UA 96279C2 UA A200807663 A UAA200807663 A UA A200807663A UA A200807663 A UAA200807663 A UA A200807663A UA 96279 C2 UA96279 C2 UA 96279C2
Authority
UA
Ukraine
Prior art keywords
antibody
fragment
binding
isolated antibody
human nogo
Prior art date
Application number
UAA200807663A
Other languages
English (en)
Ukrainian (uk)
Inventor
Стефанія Джейн Кліґґ
Джонатан Генрі Елліс
Волкер Ґермащевскі
Пол Ендрю Амблі
Ґеорґ Коспідас
Рус Макадам
Рабіндер Кумар Прінйоха
Original Assignee
Ґлаксо Ґруп Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA96279(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ґлаксо Ґруп Лімітед filed Critical Ґлаксо Ґруп Лімітед
Publication of UA96279C2 publication Critical patent/UA96279C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к изолированному антителу или его фрагменту, способному к связыванию с человеческим NOGO, нуклеиновой кислоты, которая его кодирует, вектора, клетки-хозяина, способа получения данного антитела. Изобретение также относится к фармацевтической композиции, которая содержит антитело, и применение данного антитела для приготовления лекарственного средства для лечения или профилактики инсульта и других неврологических заболеваний.
UAA200807663A 2005-12-16 2006-12-14 Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogo UA96279C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins

Publications (1)

Publication Number Publication Date
UA96279C2 true UA96279C2 (ru) 2011-10-25

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200807663A UA96279C2 (ru) 2005-12-16 2006-12-14 Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogo

Country Status (30)

Country Link
US (2) US8362208B2 (ru)
EP (2) EP1960429B1 (ru)
JP (1) JP5015949B2 (ru)
KR (1) KR101355118B1 (ru)
CN (1) CN101374863B (ru)
AR (1) AR057239A1 (ru)
AU (1) AU2006325228B2 (ru)
BR (1) BRPI0619855A2 (ru)
CA (1) CA2633501C (ru)
CR (1) CR10099A (ru)
CY (1) CY1113094T1 (ru)
DK (1) DK1960429T3 (ru)
EA (1) EA015536B1 (ru)
ES (1) ES2389380T3 (ru)
GB (1) GB0525662D0 (ru)
HR (1) HRP20120684T1 (ru)
IL (1) IL192086A0 (ru)
JO (1) JO2795B1 (ru)
MA (1) MA30041B1 (ru)
MY (1) MY149492A (ru)
NO (1) NO20082699L (ru)
NZ (1) NZ569143A (ru)
PE (1) PE20071099A1 (ru)
PL (1) PL1960429T3 (ru)
PT (1) PT1960429E (ru)
SI (1) SI1960429T1 (ru)
TW (1) TWI378940B (ru)
UA (1) UA96279C2 (ru)
WO (1) WO2007068750A2 (ru)
ZA (2) ZA200805111B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008317724B2 (en) * 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
UY31807A (es) 2008-05-06 2009-12-14 Glaxo Group Ltd Encapsulación de agentes biológicamente activos
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
IN2014KN02952A (ru) 2012-07-05 2015-05-08 Glaxo Group Ltd
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
US11013815B2 (en) 2017-06-14 2021-05-25 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
MX2021015473A (es) * 2019-06-13 2022-04-20 Prestige Biopharma Pte Ltd Nuevo anticuerpo específico para cthrc1 y su uso.
WO2021079002A2 (en) 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
JP2024526122A (ja) 2021-06-17 2024-07-17 ペットメディックス・リミテッド 抗イヌｃｄ２０抗体
WO2023067358A1 (en) 2021-10-21 2023-04-27 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
IL314314A (en) 2022-02-09 2024-09-01 Petmedix Ltd Therapeutic antibodies
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
KR20250141832A (ko) 2023-02-09 2025-09-29 펫메딕스 리미티드 P75 뉴로트로핀 수용체(p75ntr)의 세포외 도메인 변이체를 포함하는 치료 분자
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
RO114445B1 (ro) 1994-05-27 1999-04-30 Smithkline Beecham S.P.A. Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
CA2225691A1 (en) 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
DE69942803D1 (de) 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
WO2000031235A2 (en) 1998-11-06 2000-06-02 Schwab Martin E Nucleotide and protein sequences of nogo genes and methods based thereon
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
US7988964B2 (en) * 2003-12-22 2011-08-02 Glaxo Group Limited NOGO-a neutralising immunoglobulin for treatment of neurological diseases
JP4782700B2 (ja) * 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
EP1786463A4 (en) * 2004-03-26 2009-05-20 Human Genome Sciences Inc ANTIBODY AGAINST NOGO RECEPTOR

Also Published As

Publication number Publication date
JP2009519025A (ja) 2009-05-14
BRPI0619855A2 (pt) 2011-10-25
CA2633501A1 (en) 2007-06-21
EP2228391A3 (en) 2010-12-29
EP2228391A2 (en) 2010-09-15
EP1960429A2 (en) 2008-08-27
CR10099A (es) 2008-09-22
EP1960429B1 (en) 2012-06-27
GB0525662D0 (en) 2006-01-25
NZ569143A (en) 2011-08-26
CN101374863B (zh) 2013-05-29
ZA200906162B (en) 2010-05-26
EA015536B1 (ru) 2011-08-30
DK1960429T3 (da) 2012-09-24
SI1960429T1 (sl) 2012-09-28
US8362208B2 (en) 2013-01-29
NO20082699L (no) 2008-09-08
KR101355118B1 (ko) 2014-02-06
WO2007068750A3 (en) 2007-11-29
US20130287781A1 (en) 2013-10-31
IL192086A0 (en) 2008-12-29
ZA200805111B (en) 2009-12-30
CA2633501C (en) 2015-03-31
JO2795B1 (en) 2014-03-15
TWI378940B (en) 2012-12-11
CY1113094T1 (el) 2016-04-13
HK1119720A1 (en) 2009-03-13
ES2389380T3 (es) 2012-10-25
EA200801343A1 (ru) 2008-12-30
AR057239A1 (es) 2007-11-21
CN101374863A (zh) 2009-02-25
WO2007068750A2 (en) 2007-06-21
HRP20120684T1 (hr) 2012-09-30
US20100221260A1 (en) 2010-09-02
PT1960429E (pt) 2012-09-25
AU2006325228B2 (en) 2011-12-15
MA30041B1 (fr) 2008-12-01
MY149492A (en) 2013-09-13
TW200801038A (en) 2008-01-01
KR20080080644A (ko) 2008-09-04
PL1960429T3 (pl) 2012-11-30
JP5015949B2 (ja) 2012-09-05
AU2006325228A1 (en) 2007-06-21
PE20071099A1 (es) 2007-11-22

Similar Documents

Publication Publication Date Title
MX2010003574A (es) Anticuerpos il-23.
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
MX361728B (es) Ácido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilación para incrementar la expresión de un antígeno tumoral codificado.
WO2017191274A3 (en) Rna encoding a therapeutic protein
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
WO2010021874A3 (en) Engineered anti-il-13 antibodies, compositions, methods and uses
MX2007003013A (es) Amidas biciclicas como inhibidores de cinasa.
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
UA96922C2 (en) Il-12/p40 binding protein
MX2009003093A (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
CL2007001840A1 (es) Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de adn que lo codifica; vector y celula huesped que la comprenden; proceso de produccion; preparacion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de patologias mediadas por il-17.
DE60028970D1 (de) An her2 bindende peptidverbindungen
JO2576B1 (en) Antibodies
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
MX2008009886A (es) Anticuerpos que enlazan par-2.
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
TW200716646A (en) (S)-N-methylnaltrexone
MXPA05010830A (es) Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana.
WO2006081826A3 (en) Survivin peptide vaccine
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2009062195A3 (en) Fusion proteins of mannose binding lectins for treatment of disease
UA96141C2 (ru) Нейтрализующее антитело, которое имеет специфичность к человеческому il-6